Investor Portal
Tenaya Therapeutics appoints Tim Hoey, PH.D. as Chief Scientific Officer
SOUTH SAN FRANCISCO, Calif., November 1, 2017 – Tenaya Therapeutics, Inc., a privately-held biotech start-up dedicated to the discovery and development of novel therapeutics for the treatment of heart failure, announced the appointment of Tim Hoey, Ph.D. as chief scientific officer. Dr. Hoey is a biopharmaceutical executive with over two decades of experience in the industry.
Before joining Tenaya, he was senior vice president of Cancer Biology and co-chief scientific officer at OncoMed, where he led preclinical development and advanced multiple first-in-class agents to clinical testing. He also played a key role in establishing multiple corporate partnerships. Dr. Hoey entered the biotech industry as a scientist at Tularik, rising to a leadership role which he continued after Tularik’s acquisition by Amgen. Throughout his career, he has successfully led research teams in the discovery of drug targets and therapeutic agents in diverse fields including immunology, inflammation, and oncology.
“Tim Hoey brings a unique combination of scientific research prowess, drug development proficiency, and leadership needed for the realization of Tenaya’s ambitious goals,” said JJ Kang, Ph.D., president of Tenaya. “He has the vision and expertise required to advance our novel therapeutic strategies into viable clinical candidates.”
“Tenaya is an exciting new company with a talented team built on a great scientific foundation of discoveries by its founders” said Dr. Hoey. “We are focused on using innovative strategies to develop a new generation of therapeutics for the treatment heart failure, an area of tremendous medical need.”
About Tenaya Therapeutics, Inc.
Tenaya Therapeutics is a privately-held biopharmaceutical company backed by The Column Group and founded by leading scientists from The Gladstone Institute’s Cardiovascular Division and The University of Texas Southwestern Medical Center. Tenaya is dedicated to addressing heart failure through a multipronged effort that targets the fundamental cellular pathologies present in diseased cardiac muscle and leverages cutting-edge research in cardiac development and regeneration.
Tenaya Therapeutics is headquartered in South San Francisco, California. For more information, please visit the Company’s website at https://www.tenayatherapeutics.com.